Core Insights - Nexalin Technology, Inc. has received a Notice of Allowance from the USPTO for its patent on the DIFS™ technology aimed at treating substance use disorders [1][2][3] - The DIFS™ technology is a non-invasive, drug-free method designed to assist individuals with various substance use disorders, including opioid, alcohol, and stimulant addictions [1][2] - The newly allowed patent enhances Nexalin's intellectual property portfolio and positions the company as a leader in innovative medical technology [2][3] Company Overview - Nexalin Technology focuses on developing neurostimulation products to address the global mental health crisis, utilizing bioelectronic medical technology [5] - The company's DIFS™ technology aims to provide relief for mental health issues without adverse side effects, with existing products approved in multiple countries [5] Industry Context - Substance use disorders, including opioid addiction and alcoholism, are significant public health challenges affecting millions globally [2][3] - Traditional treatment methods, such as medication-assisted treatment and behavioral therapy, face issues related to accessibility and side effects, highlighting the need for alternative solutions like Nexalin's DIFS™ technology [2][3]
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders